RT @NatRevNeurol: Interim results from 1st year of Genzyme's extension study of alemtuzumab in MS suggest maintenance of drug benefits h ... 1 month ago
RT @NatRevNeurol: New data reveals that fingolimod reduces rate of both brain volume loss and relapse compared w/ IFNbeta-1a or placebo ... 1 month ago